




CV Template of KATRD International Conference 2021

Name	Jan Heyckendorf			
First Name	Jan	Last Name	Heyckendorf	
Country	Germany			
Organization	Research Center Borstel			
Current Position	Deputy Head of Medical Clinic Borstel			

Educational Background

Jan Heyckendorf is a medical doctor with specialization in respiratory care and intensive care. He was also trained in molecular biology.

Professional Experiences

He was working at different university hospitals in Germany (Hamburg, Lübeck) and spend most of his professional career at the medical clinic of the Research Center Borstel. Currently, he is the deputy head of the medical clinic and the head of endoscopy. Also, he was been working as a clinician scientist in the field of tuberculosis. His main focus was personalized medicine for patients with drug-resistant TB.

Professional Organizations

ERS, DGIM, DGP

Main Scientific Publications

Swarm Learning for decentralized and confidential clinical machine learning.

Warnat-Herresthal S, Schultze H, Shastry KL, Manamohan S, Mukherjee S, Garg V, Sarveswara R, Händler K, Pickkers P, Aziz NA, Ktena S, Tran F, Bitzer M, Ossowski S, Casadei N, Herr C, Petersheim D, Behrends U, Kern F, Fehlmann T, Schommers P, Lehmann C, Augustin M, Rybniker J, Altmüller J, Mishra N, Bernardes JP, Krämer B, Bonaguro L, Schulte-Schrepping J, De Domenico E, Siever C, Kraut M, Desai M, Monnet B, Saridaki M, Siegel CM, Drews A, Nuesch-Germano M, Theis H, Heyckendorf J, Schreiber S, Kim-Hellmuth S; COVID-19 Aachen Study (COVAS), Nattermann J, Skowasch D, Kurth I, Keller A, Bals R, Nürnberg P, Rieß O, Rosenstiel P, Netea MG, Theis F, Mukherjee S, Backes M, Aschenbrenner AC, Ulas T; Deutsche COVID-19 Omics Initiative (DeCOI), Breteler MMB, Giamarellos-Bourboulis EJ, Kox M, Becker M, Cheran S, Woodacre MS, Goh EL, Schultze JL.

Nature. 2021 Jun;594(7862):265-270. doi: 10.1038/s41586-021-03583-3. Epub 2021 May 26. PMID: 34040261 **Free PMC article.**

Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.

Heyckendorf J, Marwitz S, Reimann M, Avsar K, DiNardo A, Günther G, Hoelscher M, Ibraim E, Kalsdorf B, Kaufmann SHE, Kontsevaya I, van Leth F, Mandalakas AM, Maurer FP, Müller M, Nitschkowski D, Olaru ID, Popa C, Rachow A, Rolling T, Rybniker J, Salzer HJF, Sanchez-Carballo P, Schuhmann M, Schaub D, Spinu V, Suárez I, Terhalle E, Unnewehr M, Weiner J 3rd, Goldmann T, Lange C.

Eur Respir J. 2021 Feb 11:2003492. doi: 10.1183/13993003.03492-2020. Online ahead of print. PMID: 33574078



Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.

Bernardes JP, Mishra N, Tran F, Bahmer T, Best L, Blase JI, Bordoni D, Franzenburg J, Geisen U, Josephs-Spaulding J, Köhler P, Künstner A, Rosati E, Aschenbrenner AC, Bacher P, Baran N, Boysen T, Brandt B, Bruse N, Dörr J, Dräger A, Elke G, Ellinghaus D, Fischer J, Forster M, Franke A, Franzenburg S, Frey N, Friedrichs A, Fuß J, Glück A, Hamm J, Hinrichsen F, Hoepfner MP, Imm S, Junker R, Kaiser S, Kan YH, Knoll R, Lange C, Laue G, Lier C, Lindner M, Marinos G, Markewitz R, Nattermann J, Noth R, Pickkers P, Rabe KF, Renz A, Röcken C, Rupp J, Schaffarzyk A, Scheffold A, Schulte-Schrepping J, Schunk D, Skowasch D, Ulas T, Wandinger KP, Wittig M, Zimmermann J, Busch H, Hoyer BF, Kaleta C, Heyckendorf J, Kox M, Rybniker J, Schreiber S, Schultze JL, Rosenstiel P; HCA Lung Biological Network; Deutsche COVID-19 Omics Initiative (DeCOI). *Immunity*. 2020 Dec 15;53(6):1296-1314.e9. doi: 10.1016/j.immuni.2020.11.017. Epub 2020 Nov 26. PMID: 33296687 **Free PMC article.**

Relapse-free cure from multidrug-resistant tuberculosis in Germany.

Heyckendorf J, van Leth F, Kalsdorf B, Olaru ID, Günther G, Salzer HJF, Terhalle E, Rolling T, Glatki G, Müller M, Schuhmann M, Avsar K, Lange C. *Eur Respir J*. 2018 Feb 21;51(2):1702122. doi: 10.1183/13993003.02122-2017. Print 2018 Feb. PMID: 29467205 **Free article.** No abstract available.

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. *Antimicrob Agents Chemother*. 2018 Jan 25;62(2):e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb. PMID: 29133554 **Free PMC article.**

